Evaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation study
Authors' conclusion
This simulation study suggests that ADM tapering, in children with JIA who reached remission, may be applicable.
Study context
- Population
- Virtual children and adolescents with juvenile idiopathic arthritis (JIA) in remission on adalimumab (ADM)virtual patients
- Comparison
- ADM dose reduction to 30 mg every other week (EOW), interval extension to 21 or 28 days and therapeutic drug monitoring (TDM)-guided tapering vs label dosing
- Outcome
- Proportion of virtual patients within target exposure range 4-9 mg/L, vs label dosing, stratified by body weight
Methodological detailspreviously established pharmacokinetic model, virtual patients, stratified by body weight
- Previously established pharmacokinetic model
- Virtual patients
- Stratified by body weight
Main finding
As reported in the abstract
Proportion within target range (4-9 mg/L), children 30 to 50 kg
Label dosing
17 - 29%
Interval extension 21 days
34-43%
30 mg EOW
28-43%
TDM-guided tapering
56-63%
Safety
Proportion with trough concentrations < 2 mg/L (underexposure)
- TDM-guided tapering similar to label dosing
- ≤ 2%
Original publication
Evaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation study. Pediatr Rheumatol Online J. Published 22 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →